MYCN and neuroblastoma: High-dose chemotherapy and ASCT would not seem to be required in this subgroup of HR-NB cases in the anti-GD2 immunotherapy era since similar excellent results have been reported for locoregional MYCN-amplified patients receiving [65] or not receiving myeloablative therapies [49,66,67].